The single thing that separates a good telehealth GLP-1 program from a bad one is pharmacy accountability. Anyone can write a prescription. Fewer providers can name the specific facility filling it, show you the lot tracking, and prove the medication left a licensed compounding lab.
Here is how the ten programs I researched stack up.
Quick Comparison
| # | Provider | Starting Price | Pharmacy Transparency | Ships To | Physician Review | Notable Edge |
| 1 | HealthRX | $99/mo sema, $149/mo tirz | Named 503A pharmacy (Manifest, SC), lot-tracked, LegitScript cert | All 50 states | ~24 hrs | Free overnight shipping, cash pricing |
| 2 | FormBlends | ~$299 sema, ~$349 tirz per vial | FDA-registered 503A, published HPLC/mass spec/endotoxin data | 47 states | Physician oversight | Purity reports + peptide catalog |
| 3 | Mochi Health | ~$99/mo sema, ~$199/mo tirz | Compounded, less detail public | Most states | Board-certified obesity medicine MDs | Heavy clinical monitoring |
| 4 | Form Health | ~$299/mo + labs + meds | Branded and compounded | Most states | MD + registered dietitian | Premium co-management model |
| 5 | Hims & Hers | ~$249/mo oral, ~$299 Wegovy, ~$399 Zepbound | Branded post-March 2026 settlement | All 50 states | Async | Insurance/savings card can reach $0-25 |
| 6 | Ro Body | ~$39 first mo, ~$74-149 ongoing + meds | Prior-auth team, branded preferred | Most states | Async | Insurance prior-auth support |
| 7 | Henry Meds | ~$179-249 month one | Compounded, fast 24-72h ship | Most states | Async | Speed, cash-pay simplicity |
| 8 | Found | ~$99/mo platform + meds separate | Compounded/branded mix | Most states | Async | Behavioral coaching included |
| 9 | PlushCare | ~$19.99/mo membership + meds | Branded, insurance-accepted | Most states | Same-day visits available | Fastest consult access |
| 10 | WeightWatchers Clinic | ~$74/mo + meds | Branded | Most states | Async | Familiar behavior-change ecosystem |
1. HealthRX
Price is the first thing most people check. At $99 per month for compounded semaglutide and $149 for tirzepatide, HealthRX sits at the low end of the cash-pay market without hiding that fact behind a vague “starting at” footnote.
What earns it the top slot here is the pharmacy piece. Prescriptions go to Manifest Pharmacy in Greer, South Carolina, a 503A compounder operating under USP-797 standards with lot tracking from formulation to your door. The LegitScript certification (number 50087439) is publicly verifiable. A lot of telehealth providers describe their pharmacy as “a licensed compounding facility” and stop there. HealthRX names the building.
Physician review happens within roughly 24 hours of submitting your health assessment. Overnight shipping is included, and the program reaches all 50 states. The clinical data cited ties back to published trials: tirzepatide showed around 21% body weight reduction at 72 weeks in SURMOUNT-1, semaglutide around 15% at 68 weeks in STEP 1. Those are trial populations, not guarantees for any individual.
Compounded medications are not FDA-approved products. That is true across this entire category, and it matters.
2. FormBlends
If you want documentation before you inject anything, FormBlends is the pick. The company publishes per-product purity testing, including HPLC purity percentages, mass spectrometry identity confirmation, and endotoxin and sterility results, for its compounded GLP-1 medications. That level of paperwork is rare among telehealth providers.
Pricing runs higher than HealthRX, around $299 for semaglutide and $349 for tirzepatide per vial. Shipping reaches 47 states rather than all 50. Physician oversight is part of the model, and the same clinical framework also covers a broader peptide catalog covering areas like recovery and cognitive health, which most GLP-1-only telehealth operations do not offer at all.
This is the right option if published analytical testing justifies spending more, or if you want GLP-1 therapy and additional peptides from one provider under consistent clinical supervision.
3. Mochi Health
Mochi charges around $99 per month for compounded semaglutide and $199 for tirzepatide. The standout here is clinician quality: the platform uses board-certified obesity medicine physicians rather than general practitioners reviewing charts async. More check-ins, more structured monitoring. For anyone with a complicated metabolic history, that extra clinical attention is worth the slightly higher tirz price compared to some competitors.
4. Form Health
The most expensive option on this list by a real margin. Form Health pairs a physician with a registered dietitian, bills around $299 per month plus labs and medication costs, and builds a genuinely collaborative care plan. This is not a prescription-and-ship operation. If you have tried medication-only approaches and want the nutrition side handled simultaneously, Form Health is one of the only telehealth options structured to do that.
5. Hims & Hers
After the March 2026 Novo Nordisk settlement, Hims & Hers shifted away from compounded GLP-1s toward branded medications. Wegovy runs around $299 per month through the platform, oral semaglutide around $249, and Zepbound around $399. With insurance plus a manufacturer savings card, some users land at $0 to $25 per month. If you have solid insurance and want branded product, this is a realistic path. Without insurance, the math gets painful fast.
6. Ro Body
Ro’s first-month fee is around $39, then $74 to $149 monthly, with medications billed separately. The prior authorization team is a real differentiator. Getting branded GLP-1s approved through insurance is time-consuming and confusing. Ro assigns staff to manage that process, which has genuine value for anyone who has fought with a pharmacy benefits manager before.
7. Henry Meds
Straightforward cash-pay compounded GLP-1s, starting around $179 to $249 for month one, with shipping in 24 to 72 hours. Clinical oversight is less intensive than what Mochi or Form Health provide. Speed is the selling point here, and it delivers on that.
8. Found
Around $99 per month for platform access, medications priced separately. Found layers behavioral coaching onto the prescription side, which is a meaningful addition if accountability tools actually change your habits. Medication selection includes both compounded and branded options depending on your state and eligibility.
9. PlushCare
PlushCare is primarily an urgent and primary care telehealth service that happens to prescribe GLP-1 medications. The membership is around $19.99 per month. Same-day appointments are often available, which beats the typical 24 to 48 hour async review window by a wide margin. Insurance is accepted for branded prescriptions. Not a weight-loss-specific program, but faster access than most.
10. WeightWatchers Clinic
WW Clinic charges around $74 per month for the program, with medication costs on top. The behavior-change infrastructure that WeightWatchers built over decades actually integrates here rather than just being a marketing line. If the medication alone is not going to be enough and you want a community-and-habit system you already know, this combination makes practical sense.
What to Check Before Signing Up
Early 2026 brought FDA warning letters to more than 30 compounding telehealth companies. Regulatory pressure on this category is real and ongoing. Verify that any provider you choose uses a licensed 503A pharmacy and check whether their LegitScript status is current. Lilly’s oral orforglipron became available around April 2026 through LillyDirect at roughly $149 per month, which is worth tracking as an alternative if injectables are a barrier for you.
Common Questions
Does it actually matter which 503A pharmacy fills my compounded GLP-1 prescription?
Yes, meaningfully. Not all 503A pharmacies operate at the same standard. Facilities like Manifest Pharmacy publish lot tracking and operate under USP-797 sterility guidelines. Others do not disclose those details publicly. If your provider cannot name the specific pharmacy and confirm its LegitScript or state board status, that is a real gap worth pressing on before you pay.
If I have insurance, which of these programs gives me the best shot at getting branded Wegovy or Zepbound covered?
Ro Body is the strongest option here. Its dedicated prior authorization team handles the insurer back-and-forth on your behalf, which matters because GLP-1 prior auth requests are routinely denied on the first submission. Hims & Hers is also worth considering if your plan accepts their savings card pathway, which can bring out-of-pocket cost down to $0 to $25 per month for qualifying patients.
What separates Mochi Health from a lower-cost async program like Henry Meds or Found?
The physician type. Mochi uses board-certified obesity medicine physicians, a specialty credential that requires dedicated training beyond a general medical license. Henry Meds and Found rely on async physician review without that specialization emphasis. For patients with straightforward goals and no complex history, that difference may not matter much. For anyone with prior metabolic conditions or medication sensitivities, it probably does.
FormBlends publishes HPLC and mass spectrometry data. What does that actually tell me?
HPLC measures purity by separating compounds in a sample and quantifying each one. Mass spectrometry confirms molecular identity. Together they verify that what is in the vial is semaglutide or tirzepatide at the labeled concentration, not a degraded or mislabeled product. Most telehealth GLP-1 providers do not publish this data at all. FormBlends making it available per product is genuinely uncommon in this space.
Is orforglipron through LillyDirect a real alternative to the injectable programs listed here?
Potentially, for people who will not or cannot self-inject. Lilly’s oral orforglipron became available through LillyDirect around April 2026 at roughly $149 per month, which undercuts most injectable compounded programs on price. Trial data is not yet as extensive as the STEP 1 or SURMOUNT-1 datasets behind semaglutide and tirzepatide, so long-term outcome comparisons are not yet possible. Worth watching as the evidence base grows.
Sources
- FDA: 503A Compounding Pharmacy Regulations and 2026 Warning Letter Releases (fda.gov)
- Jastreboff et al., *New England Journal of Medicine*, 2022 (SURMOUNT-1 tirzepatide trial)
- Wilding et al., *New England Journal of Medicine*, 2021 (STEP 1 semaglutide trial)
- Novo Nordisk settlement announcement, March 9, 2026 (Reuters, STAT News coverage)
- Eli Lilly press release on orforglipron availability and pricing through LillyDirect, April 2026
- LegitScript pharmacy certification database (legitscript.com)
